Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 24

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---
 — — 218 218 Net loss— — — (19,717)— (19,717)Balance September 30, 2024189,438,135 $1,407,595 $81,425 $(1,334,040)$(48,090)$106,890 

See accompanying notes to the condensed consolidated financial statements.

4

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands of U.S. Dollars)

 Nine Months Ended September 30, 20252024OPERATING ACTIVITIESNet loss$(29,745)$(57,388)Non-cash items:Depreciation352 1,047 Loss on impairment of leasehold improvements and lab equipment2,811 167 Stock-based compensation expense5,691 7,354 Change in fair value of contingent consideration827 735 Non-cash royalty revenue(1,223)(1,736)Non-cash interest expense78 98 Net accretion and amortization of investments in marketable securities(1,927)(2,212)Net change in operating items:Accounts receivable1,504 168 Prepaid expenses and other assets400 1,145 Accounts payable and accrued liabilities(2,911)(2,727)Change in deferred license revenue(10,434)(880)Other liabilities(380)(306)Net cash used in operating activities(34,957)(54,535)INVESTING ACTIVITIESPurchase of investments in marketable securities(114,514)(98,318)Proceeds from sale of property and equipment9 — Disposition of investments in marketable securities131,446 107,951 Acquisition of property and equipment— (96)Net cash provided by investing activities16,941 9,537 FINANCING ACTIVITIESIssuance of common shares pursuant to the Open Market Sale Agreement— 44,124 Issuance of common shares pursuant to exercise of stock options3,900 6,055 Issuance of common shares pursuant to ESPP181 396 Net cash provided by financing activities4,081 50,575 Effect of foreign exchange rate changes on cash and cash equivalents13 (16)(Decrease) / Increase in cash and cash equivalents(13,922)5,561 Cash and cash equivalents, beginning of period36,330 26